CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 63 enrolled
Drug / intervention
Zegerid +1 moredrug
Likely dose
Zegerid 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01005719
NCT01005719Phase 3Completed
CompareCT.gov

Randomized, Crossover, Pharmacodynamic Study Comparing the Effects of Two Proton Pump Inhibitors

Bayer·interventional·Posted Nov 2, 2009·Updated Mar 11, 2015

In Brief

A Phase 3 clinical trial evaluating Zegerid and Prevacid® for Human Experimentation. Completed, enrolled 63 participants.

Detailed Summary

This study will determine differences between Proton Pump Inhibitors (PPI) formulations relative to their effects on gastric acidity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Experimentation
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2, 2009
Enrollment StartSep 1, 2009
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.7 years ago

Interventions

Zegeriddrug

Zegerid (20 mg omeprazole/ 1100 mg sodium bicarbonate) taken with approximately 2 oz of water once daily for 7 days.

Prevacid®drug

Prevacid (15 mg lansoprazole) taken with approximately 2 oz of water once daily for 7 days.